Immunogen
Synthesized peptide derived from human BLMH AA range: 170-220
Specificity
This antibody detects endogenous levels of BLMH at Human/Mouse/Rat
Source
Polyclonal, Rabbit,IgG
Formulation
Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.
Dilution rate
WB 1：500-2000
Purification process (Immunogen)
The antibody was affinity-purified from rabbit serum by affinity-chromatography using specific immunogen.
Background
Bleomycin hydrolase (BMH) is a cytoplasmic cysteine peptidase that is highly conserved through evolution; however, the only known activity of the enzyme is metabolic inactivation of the glycopeptide bleomycin (BLM), an essential component of combination chemotherapy regimens for cancer. The protein contains the signature active site residues of the cysteine protease papain superfamily. [provided by RefSeq, Jul 2008],
Function
catalytic activity:Inactivates bleomycin B2 (a cytotoxic glycometallopeptide) by hydrolysis of a carboxyamide bond of beta-aminoalanine, but also shows general aminopeptidase activity. The specificity varies somewhat with source, but amino acid arylamides of Met, Leu and Ala are preferred.,function:The normal physiological role of BLM hydrolase is unknown, but it catalyzes the inactivation of the antitumor drug BLM (a glycopeptide) by hydrolyzing the carboxamide bond of its B-aminoalaninamide moiety thus protecting normal and malignant cells from BLM toxicity.,similarity:Belongs to the peptidase C1 family.,subunit:Homohexamer.,
Human protein sequence Database
Q13867
Mouse protein sequence database
Q8R016
Rat protein sequence database
P70645
Cellular localization
Cytoplasm . Cytoplasmic granule . Co-localizes with NUDT12 in the cytoplasmic granules. .
Contract Us
Follow Us
Location： 
Specification
成功添加到购物车